2024-10-25 15:42:24,198 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:24,200 - INFO - Run 0:
[Scene: A dimly lit coffee shop in Washington D.C., October 2, 2024. Nate Silver and Philip Tetlock are discussing over steaming cups of coffee.]

Nate: "So, Phil, our models were spot on again about the CDC's mpox risk assessment."

Philip: "Indeed. Looking back at the data we had until August 23rd, our models gave it only a 12.5% chance that the CDC would escalate the risk level above 'High' by October."

Nate: "The key factors were clear. Despite that concerning spread in Sub-Saharan Africa, the U.S. population maintained strong immunity levels from previous vaccination campaigns. And the July 8th assessment of 'Very Low' risk gave us a solid baseline."

Philip: "Exactly. The historical data showed that such dramatic jumps in risk assessment - from 'Very Low' to beyond 'High' in just two months - are extremely rare without a major variant emergence or complete vaccine failure. Neither materialized."

Nate: "Another win for systematic forecasting."

2024-10-25 15:42:30,321 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:30,321 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:30,322 - INFO - Run 1:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Well, Philip, our models were spot on again about the mpox risk assessment.

Philip Tetlock: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread of clade I mpox in Sub-Saharan Africa, our models predicted only a 12.5% chance of the risk exceeding "High" by October.

Nate: The key factors were strong population immunity from previous outbreaks and widely available vaccines. Even with that concerning spread in Africa, the U.S. healthcare infrastructure was well-prepared.

Philip: Exactly. The CDC maintained their "Very Low" risk assessment through September. While they monitored the situation closely, there wasn't enough evidence to suggest a dramatic shift in either likelihood or impact metrics.

Nate: [nodding] No, our models had it at 12.5%. The combination of existing preparedness and limited transmission patterns made a risk assessment above "High" highly unlikely.

2024-10-25 15:42:30,322 - INFO - Run 1:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Well, Philip, our models were spot on again about the mpox risk assessment.

Philip Tetlock: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread of clade I mpox in Sub-Saharan Africa, our models predicted only a 12.5% chance of the risk exceeding "High" by October.

Nate: The key factors were strong population immunity from previous outbreaks and widely available vaccines. Even with that concerning spread in Africa, the U.S. healthcare infrastructure was well-prepared.

Philip: Exactly. The CDC maintained their "Very Low" risk assessment through September. While they monitored the situation closely, there wasn't enough evidence to suggest a dramatic shift in either likelihood or impact metrics.

Nate: [nodding] No, our models had it at 12.5%. The combination of existing preparedness and limited transmission patterns made a risk assessment above "High" highly unlikely.

2024-10-25 15:42:36,451 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:36,451 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:36,451 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:36,452 - INFO - Run 2:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [looking at data screens] Well, Philip, another prediction in the books. The CDC's mpox risk assessment stayed at "Very Low" through September.

Philip Tetlock: [nodding] No surprise there. Our models gave only a 2.3% chance of the risk level exceeding "High." The July assessment showed minimal transmission in the general population, and even with the concerns about clade I mpox in Africa, the U.S. population maintained strong immunity levels.

Nate: The key factors were there - widespread vaccine availability, effective treatments, and learned behaviors from the 2022 outbreak. Even the Sub-Saharan spread didn't significantly impact U.S. risk metrics.

Philip: [reviewing notes] Exactly. The CDC's robust surveillance system and quick response capabilities kept the risk contained. The data simply didn't support escalation beyond "High" - our models caught that early on.

2024-10-25 15:42:36,452 - INFO - Run 2:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [looking at data screens] Well, Philip, another prediction in the books. The CDC's mpox risk assessment stayed at "Very Low" through September.

Philip Tetlock: [nodding] No surprise there. Our models gave only a 2.3% chance of the risk level exceeding "High." The July assessment showed minimal transmission in the general population, and even with the concerns about clade I mpox in Africa, the U.S. population maintained strong immunity levels.

Nate: The key factors were there - widespread vaccine availability, effective treatments, and learned behaviors from the 2022 outbreak. Even the Sub-Saharan spread didn't significantly impact U.S. risk metrics.

Philip: [reviewing notes] Exactly. The CDC's robust surveillance system and quick response capabilities kept the risk contained. The data simply didn't support escalation beyond "High" - our models caught that early on.

2024-10-25 15:42:36,452 - INFO - Run 2:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [looking at data screens] Well, Philip, another prediction in the books. The CDC's mpox risk assessment stayed at "Very Low" through September.

Philip Tetlock: [nodding] No surprise there. Our models gave only a 2.3% chance of the risk level exceeding "High." The July assessment showed minimal transmission in the general population, and even with the concerns about clade I mpox in Africa, the U.S. population maintained strong immunity levels.

Nate: The key factors were there - widespread vaccine availability, effective treatments, and learned behaviors from the 2022 outbreak. Even the Sub-Saharan spread didn't significantly impact U.S. risk metrics.

Philip: [reviewing notes] Exactly. The CDC's robust surveillance system and quick response capabilities kept the risk contained. The data simply didn't support escalation beyond "High" - our models caught that early on.

2024-10-25 15:42:43,491 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:43,491 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:43,491 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:43,491 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:43,492 - INFO - Run 3:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Phil, our models were spot on about the mpox risk assessment.

Philip Tetlock: Indeed. Despite the concerning spread of clade I mpox in Sub-Saharan Africa, our models gave only a 12.5% probability that the CDC would escalate the risk level above "High."

Nate: The data supported that. Even with the July assessment at "Very Low," the historical patterns showed minimal likelihood of such a dramatic jump in risk level within such a short timeframe.

Philip: Exactly. The U.S. population's immunity levels remained stable, and treatment accessibility stayed consistent. The containment measures in Africa also helped prevent significant spread to the U.S.

Nate: [nodding] The CDC maintained their "Very Low" assessment through September. Our models indicated that without a catastrophic mutation or complete vaccine failure, the probability of exceeding "High" was minimal.

Philip: Another win for superforecasting. Our 12.5% probability reflected the real-world outcome perfectly.

2024-10-25 15:42:43,492 - INFO - Run 3:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Phil, our models were spot on about the mpox risk assessment.

Philip Tetlock: Indeed. Despite the concerning spread of clade I mpox in Sub-Saharan Africa, our models gave only a 12.5% probability that the CDC would escalate the risk level above "High."

Nate: The data supported that. Even with the July assessment at "Very Low," the historical patterns showed minimal likelihood of such a dramatic jump in risk level within such a short timeframe.

Philip: Exactly. The U.S. population's immunity levels remained stable, and treatment accessibility stayed consistent. The containment measures in Africa also helped prevent significant spread to the U.S.

Nate: [nodding] The CDC maintained their "Very Low" assessment through September. Our models indicated that without a catastrophic mutation or complete vaccine failure, the probability of exceeding "High" was minimal.

Philip: Another win for superforecasting. Our 12.5% probability reflected the real-world outcome perfectly.

2024-10-25 15:42:43,492 - INFO - Run 3:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Phil, our models were spot on about the mpox risk assessment.

Philip Tetlock: Indeed. Despite the concerning spread of clade I mpox in Sub-Saharan Africa, our models gave only a 12.5% probability that the CDC would escalate the risk level above "High."

Nate: The data supported that. Even with the July assessment at "Very Low," the historical patterns showed minimal likelihood of such a dramatic jump in risk level within such a short timeframe.

Philip: Exactly. The U.S. population's immunity levels remained stable, and treatment accessibility stayed consistent. The containment measures in Africa also helped prevent significant spread to the U.S.

Nate: [nodding] The CDC maintained their "Very Low" assessment through September. Our models indicated that without a catastrophic mutation or complete vaccine failure, the probability of exceeding "High" was minimal.

Philip: Another win for superforecasting. Our 12.5% probability reflected the real-world outcome perfectly.

2024-10-25 15:42:43,492 - INFO - Run 3:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Phil, our models were spot on about the mpox risk assessment.

Philip Tetlock: Indeed. Despite the concerning spread of clade I mpox in Sub-Saharan Africa, our models gave only a 12.5% probability that the CDC would escalate the risk level above "High."

Nate: The data supported that. Even with the July assessment at "Very Low," the historical patterns showed minimal likelihood of such a dramatic jump in risk level within such a short timeframe.

Philip: Exactly. The U.S. population's immunity levels remained stable, and treatment accessibility stayed consistent. The containment measures in Africa also helped prevent significant spread to the U.S.

Nate: [nodding] The CDC maintained their "Very Low" assessment through September. Our models indicated that without a catastrophic mutation or complete vaccine failure, the probability of exceeding "High" was minimal.

Philip: Another win for superforecasting. Our 12.5% probability reflected the real-world outcome perfectly.

2024-10-25 15:42:50,312 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:50,312 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:50,312 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:50,312 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:50,312 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-25 15:42:50,312 - INFO - Run 4:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Well, Philip, looks like our models were spot on again regarding the mpox risk assessment.

Philip Tetlock: Indeed. Our models gave it a 12.3% probability of exceeding "High" risk before October. The CDC maintained their "Very Low" assessment through September.

Nate: Makes sense. Despite that concerning spread in Sub-Saharan Africa they mentioned in August, the U.S. population maintained strong immunity levels from previous vaccination campaigns.

Philip: Right. The key factors were the limited transmission chains in the U.S. and widely available treatments. Even with their July 8th update suggesting changes, the likelihood and impact metrics stayed well below the threshold for "High" risk.

Nate: [nodding] The data supported our low probability forecast. Between robust public health measures and learned experiences from 2022, we never saw conditions that would warrant exceeding a "High" risk assessment.

2024-10-25 15:42:50,312 - INFO - Run 4:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Well, Philip, looks like our models were spot on again regarding the mpox risk assessment.

Philip Tetlock: Indeed. Our models gave it a 12.3% probability of exceeding "High" risk before October. The CDC maintained their "Very Low" assessment through September.

Nate: Makes sense. Despite that concerning spread in Sub-Saharan Africa they mentioned in August, the U.S. population maintained strong immunity levels from previous vaccination campaigns.

Philip: Right. The key factors were the limited transmission chains in the U.S. and widely available treatments. Even with their July 8th update suggesting changes, the likelihood and impact metrics stayed well below the threshold for "High" risk.

Nate: [nodding] The data supported our low probability forecast. Between robust public health measures and learned experiences from 2022, we never saw conditions that would warrant exceeding a "High" risk assessment.

2024-10-25 15:42:50,312 - INFO - Run 4:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Well, Philip, looks like our models were spot on again regarding the mpox risk assessment.

Philip Tetlock: Indeed. Our models gave it a 12.3% probability of exceeding "High" risk before October. The CDC maintained their "Very Low" assessment through September.

Nate: Makes sense. Despite that concerning spread in Sub-Saharan Africa they mentioned in August, the U.S. population maintained strong immunity levels from previous vaccination campaigns.

Philip: Right. The key factors were the limited transmission chains in the U.S. and widely available treatments. Even with their July 8th update suggesting changes, the likelihood and impact metrics stayed well below the threshold for "High" risk.

Nate: [nodding] The data supported our low probability forecast. Between robust public health measures and learned experiences from 2022, we never saw conditions that would warrant exceeding a "High" risk assessment.

2024-10-25 15:42:50,312 - INFO - Run 4:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Well, Philip, looks like our models were spot on again regarding the mpox risk assessment.

Philip Tetlock: Indeed. Our models gave it a 12.3% probability of exceeding "High" risk before October. The CDC maintained their "Very Low" assessment through September.

Nate: Makes sense. Despite that concerning spread in Sub-Saharan Africa they mentioned in August, the U.S. population maintained strong immunity levels from previous vaccination campaigns.

Philip: Right. The key factors were the limited transmission chains in the U.S. and widely available treatments. Even with their July 8th update suggesting changes, the likelihood and impact metrics stayed well below the threshold for "High" risk.

Nate: [nodding] The data supported our low probability forecast. Between robust public health measures and learned experiences from 2022, we never saw conditions that would warrant exceeding a "High" risk assessment.

2024-10-25 15:42:50,312 - INFO - Run 4:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Well, Philip, looks like our models were spot on again regarding the mpox risk assessment.

Philip Tetlock: Indeed. Our models gave it a 12.3% probability of exceeding "High" risk before October. The CDC maintained their "Very Low" assessment through September.

Nate: Makes sense. Despite that concerning spread in Sub-Saharan Africa they mentioned in August, the U.S. population maintained strong immunity levels from previous vaccination campaigns.

Philip: Right. The key factors were the limited transmission chains in the U.S. and widely available treatments. Even with their July 8th update suggesting changes, the likelihood and impact metrics stayed well below the threshold for "High" risk.

Nate: [nodding] The data supported our low probability forecast. Between robust public health measures and learned experiences from 2022, we never saw conditions that would warrant exceeding a "High" risk assessment.

